ADC Therapeutics (ADCT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$79.6M

Revenue (quarter)

$19.2M

Revenue growth (year over year)

+2.17%

Gross profit (trailing twelve months)

$70.7M

Gross margin

88.86%

Net income (trailing twelve months)

−$96.9M

Net income (quarter)

−$16.6M

Net income growth (year over year)

+70.76%

Net margin

−121.77%

Return on equity

—

EPS (trailing twelve months)

−$0.58

Book value per share

−$1.79

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

181.68%

Payout ratio

—

Dividend yield

—

Company profile

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

• Is ADC Therapeutics (ADCT) profitable?

  No. ADC Therapeutics reported a net loss of $96.9M over the trailing twelve months.

• How much revenue does ADC Therapeutics (ADCT) make?

  ADC Therapeutics generated $79.6M in revenue over the trailing twelve months, up 2.17% year over year.

• How do I buy stock in ADC Therapeutics (ADCT)?

  ADCT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.